Related Experiment Video

Updated: Aug 4, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.6K

Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea

Jaemin Jo1, Jung Ho Kim2, Ji Young Kim1

  • 1Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea.

Cancer Research and Treatment
|February 27, 2015
PubMed

Insights

Pazopanib, a tyrosine kinase inhibitor, showed a partial response in a patient with advanced non-small cell lung cancer and renal cell carcinoma. This case suggests pazopanib may be a viable treatment option for lung cancer.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Pazopanib is an effective tyrosine kinase inhibitor for renal cell carcinoma.
  • Previous studies indicated pazopanib's antitumor activity and tolerability in early-stage non-small cell lung cancer (NSCLC).

Observation:

  • A 66-year-old male patient presented with simultaneous metastatic squamous cell carcinoma of the lung and renal cell carcinoma.
  • The patient was treated with pazopanib for his advanced cancers.

Findings:

  • The patient achieved an unexpected partial response to pazopanib treatment.
  • He experienced a 10-month progression-free survival with no significant toxicity.
  • This represents the first reported case of pazopanib use in a non-small cell lung cancer patient in Korea.

Implications:

  • Pazopanib demonstrates potential as a treatment option for advanced non-small cell lung cancer.
  • Further investigation into pazopanib for advanced NSCLC, particularly in combination with other malignancies, is warranted.
Keywords:
Drug therapyLung neoplasmsPazopanibTyrosine kinase inhibitor

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...